おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
probenecid
メーカー／製品名
USP
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
SMILES記法
CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O
InChI
1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
InChI Key
DBABZHXKTCFAPX-UHFFFAOYSA-N
遺伝子情報
human ... SLC22A11(55867) , SLC22A6(9356) , SLC22A8(9376)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
アプリケーション
Probenecid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Probenecid and Colchicine Tablets
- Probenecid Tablets
アナリシスノート
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
その他情報
Sales restrictions may apply.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
1563003-200MG:
最新バージョンのいずれかを選択してください：
Clinical pharmacokinetics of probenecid.
Cunningham, R. F., Z. H. Israili, and P. G. Dayton.
Clinical Pharmacokinetics, 6.2, 135-151 (1981)
Probenecid and zidovudine metabolism.
Kornhauser, DavidM, et al.
Lancet, 334.8661, 473-475 (1989)
R F Cunningham et al.
Clinical pharmacokinetics, 6(2), 135-151 (1981-03-01)
A review of the clinical applications and of the disposition of probenecid in man, including drug interactions, is presented. Probenecid is the classical competitive inhibitor of organic acid transport in the kidney and other organs. There are 2 primary clinical
Wei Kong et al.
American journal of physiology. Heart and circulatory physiology, 307(1), H73-H79 (2014-05-06)
Previous experiments in cultures of neonatal rat myocytes demonstrated that the shape of Cai(2+) transients measured using high-affinity Ca(2+)-sensitive dyes may be misrepresented. The purpose of this study was to examine the role of dye affinity in Cai(2+) measurements in
Dennis W Raisch et al.
Pharmacotherapy, 29(8), 988-992 (2009-07-30)
The possibility of an avian flu pandemic has spurred interest in preventive treatments with antivirals such as oseltamivir. Combining treatment with probenecid to delay excretion may extend limited supplies of oseltamivir. We previously conducted a pharmacokinetic study of oseltamivir plus
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）